



# The global leader in developing LAG-3 therapeutics

Ladenburg Thalmann 2018 Healthcare Conference  
October 2, 2018

*(ASX: IMM, NASDAQ: IMMP)*

# Notice: Forward Looking Statements

*The purpose of the presentation is to provide an update of the business of Immunetep Limited ACN 009 237 889 (ASX:IMM; NASDAQ:IMMP). These slides have been prepared as a presentation aid only and the information they contain may require further explanation and/or clarification. Accordingly, these slides and the information they contain should be read in conjunction with past and future announcements made by Immunetep and should not be relied upon as an independent source of information. Please refer to the Company's website and/or the Company's filings to the ASX and SEC for further information.*

*The views expressed in this presentation contain information derived from publicly available sources that have not been independently verified. No representation or warranty is made as to the accuracy, completeness or reliability of the information. Any forward looking statements in this presentation have been prepared on the basis of a number of assumptions which may prove incorrect and the current intentions, plans, expectations and beliefs about future events are subject to risks, uncertainties and other factors, many of which are outside Immunetep's control. Important factors that could cause actual results to differ materially from assumptions or expectations expressed or implied in this presentation include known and unknown risks. Because actual results could differ materially to assumptions made and Immunetep's current intentions, plans, expectations and beliefs about the future, you are urged to view all forward looking statements contained in this presentation with caution.*

*Additionally, the INSIGHT investigator sponsored clinical trial described in this presentation is controlled by the lead investigator and therefore Immunetep has no control over this clinical trial. This presentation should not be relied on as a recommendation or forecast by Immunetep. Nothing in this presentation should be construed as either an offer to sell or a solicitation of an offer to buy or sell shares in any jurisdiction.*

# Company Snapshot

- Globally active biotechnology company with operations in Australia, Europe and U.S.
- Four LAG-3 related product candidates in development in immuno-oncology and autoimmune disease
- Committed partnerships with three of the world's largest pharmaceutical companies - Merck (MSD), Novartis and GSK, along with Eddingpharm in China

## Capital Structure


<b>Ticker symbols</b>	IMMP (NASDAQ - ADRs) IMM (Australian Securities Exchange)
<b>Securities on issue</b> (as at 28 September 2018)	3.0 billion ordinary shares 8.1 million issued ADRs
<b>Cash &amp; Term Deposits<sup>(1)</sup></b> (as at 30 June 2018)	US\$18.8 million (~A\$25.4 million)
<b>Market Cap</b> (as at 28 September 2018)	US\$112.2 million (~A\$155.4 million)
<b>Avg. Vol. (3 months)</b> (as at 28 September 2018)	118 k ADRs on NASDAQ 4.5 million ordinary shares on ASX

*Notes:*

<sup>(1)</sup> Pro forma A\$1.9mm (US\$1.4mm) R&D rebate received from the French government (21 August 2018)

Market capitalisation based on Nasdaq ADR share price. For a detailed summary of all securities on issue refer to latest Appendix 3B released on ASX. Each ADR represents 100 ordinary shares


## Shareholders



■ Australian Securities Exchange  
■ Nasdaq

# LAG-3 as a Therapeutic Target

LAG-3 is widely expressed on tumor infiltrating lymphocytes (TILs) and cytotoxic T cells →  
**Prime target for an immune checkpoint blocker**




→ **Positive regulation** of antigen presenting cells (APC) → increase in antigen presentation to cytotoxic CD8<sup>+</sup> T cells

→ **Negative regulation** of LAG-3<sup>+</sup> T Cells

*Notes:*  
\* APC: antigen presenting cell

# Targeting LAG-3 May Lead to Multiple Therapeutics in Numerous Indications



# Oncology and Autoimmune Pipeline\*

Program	Preclinical	Phase I	Phase II	Late Stage	Commercial Rights/Partners
Eftilagimod Alpha (LAG-3lg or IMP321), APC activating fusion protein	AIPAC (Chemo-IO Combo)			2019 <sup>(1)</sup>	Global Rights Chinese Rights
	TACTI-002 <sup>(2),(6)</sup> (IO-IO Combo)		2019/2020 <sup>(1)</sup>	MERCK INVENTING FOR LIFE	
	INSIGHT-004 <sup>(3),(4),(6)</sup> (IO-IO Combo)		2019/2020 <sup>(1)</sup>	Pfizer Merck KGaA, Darmstadt, Germany	
	TACTI-mel (IO-IO Combo)		2018/2019 <sup>(1)</sup>		
	INSIGHT <sup>(3)</sup> (In situ Immunization)		2018/2019 <sup>(1)</sup>		
IMP731 (Depleting AB)	Autoimmune Diseases <sup>(5)</sup>				Global Rights
IMP701 (Antagonist AB)	IO-IO Combo: solid tumors IO-IO Combo: solid tumors + blood cancer Chemo-IO combo: metastatic breast cancer IO-IO Combo: melanoma				Global Rights
IMP761 (Agonist AB)	Autoimmune Diseases				Global Rights




Notes

- (1) Expected timing of data readouts and actual results and timing may differ
- (2) In combination with KEYTRUDA® (pembrolizumab) in non-small cell lung carcinoma ("NSCLC") or head and neck carcinoma ("HNSCC"); clinical trial is currently planned and not active
- (3) INSIGHT Investigator Initiated Trial ("IIT") is controlled by lead investigator and therefore ImmuteP has no control over this clinical trial

- (4) In combination with BAVENCIO® (avelumab)
- (5) Reflects completed study in psoriasis
- (6) Clinical trial is currently planned and not active
- \* Cell Therapy: CVac™ - divested to and controlled by Sydys Corporation

# LAG-3 Therapeutic Landscape Overview

*Immutep is the leader in developing LAG-3 modulating therapeutics*




Indicates one product; size indicates stage of development, green = product either developed by Immutep or under license from Immutep

Indicates No. of patients on trials

Sources: GlobalData, company websites, clinical trials.gov, and sec.gov

Information as of August 17, 2018, includes planned and completed trials, includes trials where the company may not be the sponsor



# Lead product candidate: Eftilagimod Alpha




**Eftilagimod has the potential to be an ideal combination candidate in oncology therapy that could improve the prognosis for patients**

## **Eftilagimod Key Characteristics (based on current data):**

- First in class MHCII agonist
- Excellent safety profile and encouraging efficacy data thus far
- Potential for use in various combination settings (e.g. IO, chemo, vaccines or in situ immunization)
- Estimated favorable (low) cost of goods based on current flat dosing regimen and manufacturing process







# Efti (IMP321) in Melanoma

## TACTI-mel (IO combination) – Single Case at 1 mg efti



### Efficacy: Metastatic Melanoma



**All lesions disappeared → CR (confirmed) patient without treatment and disease free**

## Potential News Flow and Milestones

### Clinical

TACTI-mel data from fourth patient cohort (30 mg dose at cycle 1): H2 2018

TACTI-002 to commence, Phase II clinical trial in collaboration with MSD: H2 2018

INSIGHT-004<sup>(1)</sup> to commence, Phase I clinical trial in collaboration with Pfizer/ Merck KGaA: H2 2018

TACTI-002 first data in 2019

IMP761 preclinical data: 2018/ 2019

INSIGHT single cases from study: throughout 2019

AIPAC progression free survival data (metastatic breast cancer trial): 2019

### Other

Potential milestone payments from clinical partners as trials progress

Continued expansion of patent portfolio

Continued regulatory interaction

Ongoing business development activities

**Thank you!**